Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T, Yamashita T, Takata N, Takeda Y, Kido H, Iida N, Kitahara M, Shimakami T, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S.
Terashima T, et al. Among authors: takeda y.
Hepatol Res. 2021 Feb;51(2):190-200. doi: 10.1111/hepr.13588. Epub 2020 Dec 4.
Hepatol Res. 2021.
PMID: 33197087